Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Assets: 2019-2025

Historic Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $998.2 million.

  • BridgeBio Pharma's Assets rose 50.12% to $998.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $998.2 million, marking a year-over-year increase of 50.12%. This contributed to the annual value of $919.3 million for FY2024, which is 68.26% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Assets stood at $998.2 million, which was down 7.59% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Assets peaked at $1.1 billion during Q1 2021, and registered a low of $503.7 million during Q2 2023.
  • Over the past 3 years, BridgeBio Pharma's median Assets value was $794.4 million (recorded in 2024), while the average stood at $774.4 million.
  • In the last 5 years, BridgeBio Pharma's Assets tumbled by 41.59% in 2023 and then surged by 68.26% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Assets (Quarterly) stood at $1.0 billion in 2021, then plummeted by 38.48% to $623.0 million in 2022, then decreased by 12.30% to $546.4 million in 2023, then soared by 68.26% to $919.3 million in 2024, then surged by 50.12% to $998.2 million in 2025.
  • Its last three reported values are $998.2 million in Q3 2025, $1.1 billion for Q2 2025, and $881.6 million during Q1 2025.